Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 917 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cancer Patients Have Been Lonelier During the COVID-19 Pandemic May 27, 2021 Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... May 3, 2023 Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with... July 23, 2026 In Memory of Håkan Mellstedt: Former ESMO President August 26, 2025 Load more HOT NEWS Breast Cancer Risk Genes Kinder and more effective – why childhood cancers need specific treatments Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Teacher Is Glad She Asked for More Testing After Mammogram Failed...
